Ticagrelor, a reversible P2Y12 inhibitor, has hepatic metabolism, being activated by the liver cytochrome 3A4 enzyme, and it is not recommended in patients with Child–Pugh class C liver cirrhosis [68]. Here, P2RY12 is linked to cirrhosis of liver.